Eigentler T, Krauss J, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, Weide B, Ochsenreither S, Becker J, Bauernfeind FG, Brossart P, Funkner F, Heidenreich R, Kays SK, Muth A, Seibel T, Scheel B, Schoenborn-Kellenberger O, Stosnach C, Daehling A, Strack T, Korolkiewicz R, Gnad-Vogt U (2019)
Publication Type: Conference contribution
Publication year: 2019
Publisher: BMC
City/Town: LONDON
Conference Proceedings Title: JOURNAL FOR IMMUNOTHERAPY OF CANCER
DOI: 10.1136/jitc-2020-sitc2020.0800
APA:
Eigentler, T., Krauss, J., Schreiber, J., Weishaupt, C., Terheyden, P., Heinzerling, L.,... Gnad-Vogt, U. (2019). A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors. In JOURNAL FOR IMMUNOTHERAPY OF CANCER. LONDON: BMC.
MLA:
Eigentler, Thomas, et al. "A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors." Proceedings of the JOURNAL FOR IMMUNOTHERAPY OF CANCER LONDON: BMC, 2019.
BibTeX: Download